Wntresearch Ab

Glactone Pharma Development Ab

Anders Bjartell

Olov Sterner

Tommy Andersson

Johansson Martin

Zilma Escobar

Rebecka Hellsten

Ether analogues of galiellalactone, methods of preparing the analogues, and use of the analogues in the treatment of cancer are disclosed. The analogues are of formula (I) or (II): 

Ether analogues of galiellalactone

The present invention relates to a Wnt5a protein or peptide thereof possessing Wnt5a signaling properties, such as Foxy5, for use in the treatment of prostate cancer, in particular in patients that have undergone or will undergo radical prosteatectomy. The invention also relates to a method for determining a prognosis for a patient having prostate cancer and a kit for performing said method. The method for determining a prognosis for a patient comprises the steps of: evaluating an amount of Wnt5a protein present in at least part of a sample earlier obtained from the patient and determining a sample value corresponding to the evaluated amount; comparing the sample value obtained in step a) with a reference value associated with a reference prognosis; and, if said sample value is higher than said reference value, concluding that the prognosis for said patient is better than said reference prognosis.

Treatment of prostate cancer and a method for determining the prognosis for prostate cancer patients

Growing community of inventors

Malmö, Sweden

Anders Bjartell